Citi raised the firm’s price target on BioMarin (BMRN) to $82 from $81 and keeps a Neutral rating on the shares. The company reported a Q4 beat, driven by commercial execution across the portfolio, the analyst tells investors in a research note. The firm expects continued Voxzogo growth, albeit at a decelerating growth rate as the franchise approaches blockbuster status.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Pharmaceutical’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- BioMarin’s Record Growth and 2025 Outlook
- Closing Bell Movers: Carvana down 8% on earnings, Palantir extends decline
- BioMarin sees FY25 EPS $4.20-$4.40, consensus $4.16
- BioMarin reports Q4 non-GAAP EPS 92c, consensus 74c